Biotechs Continue to Underperform (IBB)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Leerink Partners Reiterates Outperform on BioMarin Pharma (BMRN) Following Mixed Ph. 3 Data Results
March 21, 2016 1:17 PM EDTLeerink Partners reiterated an Outperform rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) following the company's mixed PEG-PAL Ph. 3 data. In study '302, blood Phe elevated to near-baseline levels (1385.7 uM) upon discontinuation vs. pts. continuing PEG-PAL treatment (527.2 uM) (p... More
Leerink Partners Cuts Price Target on Alexion Pharma (ALXN) to $216; Reiterates Outperform
March 18, 2016 6:48 AM EDTLeerink Partners maintained an Outperform rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and cut the price target to $216.00 (from $217.00). Conviction about the company is based on a positive outlook for Soliris [aHUS, PNH] and its potential in existing and new indications, as well as... More
